Glaucoma Clinical Trial
Official title:
The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension: An Observational Study
There are currently many surgical options for patients with glaucoma and ocular hypertension (OHT), including the Hydrus Microstent implant, HiFU (High intensity Focused ultrasound), STAR flo, Kahook Dual Blade, Diode laser, trabeculectomy and the Baerveldt implant, but little is known about how these different surgical techniques used to treat glaucoma affect the flow of fluid through and out of the eye (aqueous dynamics).
Trial objectives
Main outcome measures: The following aqueous dynamics parameters will be measured: IOP,
aqueous flow rate, trabecular outflow facility and uveoscleral outflow. These parameters
will be measured pre-treatment (up to 2 months before glaucoma surgery) and repeated 3
months and 12 months post-surgery. Measures will be taken from the operated eye and the
contra lateral non-operated eye which will be used as the control.
Trial design
This is a prospective observational study with the contra lateral untreated eye being used
as control. Baseline measures will be conducted at a routine clinic visit up to 2 months
before glaucoma surgery after 4 weeks of treatment washout.
Post-treatment follow-up measurements of the main outcomes will be conducted 3 months and 12
months after surgery, again, after 4 weeks wash out. A number of additional eye tests will
also be performed to collect data for the study at the pre-operative appointment when the
baseline measurements are taken and at the post-operative follow-up appointments 3 months
and 12 months after the surgery. Other data will be collected from eye tests that are
routinely performed pre-operatively and at the post-operative follow-up appointments 1 day,
1 week, 1 month, 3 months, 6 months, and 12 months after their surgery.
Study participants will be recruited from patients attending the Ophthalmology Department
Outpatients Clinic at St Thomas' Hospital, London, United Kingdom who have a diagnosis of
glaucoma or OHT (ocular hypertension) requiring glaucoma drainage surgery. One hundred
patients with glaucoma or OHT and where a clinical decision has been made that they need
glaucoma surgery will be included in the study such that 100 eyes undergoing surgery will be
included together with the contra-lateral untreated eyes that will be used as controls for
comparison with the treated eyes.
Data will be collected for the study at the following routine appointments that patients
undergoing glaucoma surgery are asked to attend: a pre-operative appointment, surgery, and
follow-up assessments 1 day, 1 week, 1 month, 3 months, 6 months, and 12 months after
surgery. Baseline measurements will be taken up to 2 months before glaucoma surgery.
At the baseline assessment demographic information will be collected
Details of participants' relevant past medical history will be collected at the baseline
pre-operative assessment and at 12 months post-surgery.
All tests will be performed on both eyes as the contra-lateral non-operated eye will be used
as control.
Aqueous parameters
• Aqueous flow rate: Participants will be asked to self-administer 3 to 6 drops (depending
on their age) of fluorescein sodium 2% topically into both eyes at 5 minute intervals on the
night before the fluorophotometric scans. Fluorophotometry will be performed using a
scanning ocular fluorophotometer from 9:00 am -12:00 midday. Four sets of triplicate scans
will be collected at 1 hour intervals to determine the aqueous flow rate (Ft). The 3 scans
are done in quick succession, taking approximately 2 seconds in total to complete the set.
Following each set of scans, IOP will be measured using pneumatonometry. and rebound
tonometry. IOP will be recorded as the mean of a total of 12 measurements per eye: 3
measurements every hour alternating between eyes.
Patients who have had previous cataract surgeries or iridotomy/iridectomy will be excluded
from this aspect of the measurements as fluorophotometry is inaccurate in these eyes.
- Outflow facility: Tonographic outflow facility (C) measurement will be performed using
an electronic Schiøtz tonographer (Model 720, Berkeley Bioengineering Inc, USA) between
9:00 am -12:00 midday. The facility of outflow will be measured from the rate of decay
of IOP in the supine position during application of a recording Schiøtz tonometer over
a period of 4 minutes with a standard 5.5 gram weight. The "R" values of the curve at
every 30-second time point will be manually entered into the McLaren tonography
computer program. The program fits a second-degree polynomial by least squares to the
nine data points and determines the best-fit values for time 0 and time 4 minutes by
extrapolation.
- Intraocular pressure (IOP): Pneumatonometry and rebound tonometry will be used to
measure IOP for patients undergoing fluorophotometry. The IOP measurements will be
recorded at 1 hour intervals between the hours of 9:00 am -12:00 midday following each
set of fluorophotometric scans.
- Uveoscleral outflow: There are currently no reliable clinical methods of measuring
uveoscleral outflow (Fu) and episcleral venous pressure (Pv). Fu will be therefore
calculated using the Goldmann equation (see below) with an assumed episcleral venous
pressure of 8-11 mmHg:
Ft = C(IOP - Pv) +Fu Where:
Ft = Measured aqueous flow rate Fu = Ft - C(IOP - Pv) Fu = Calculated uveoscleral outflow C
= Tonographic outflow facility (value computed by the measurement device) IOP = Mean morning
intraocular pressure as measured by pneumatonometry Pv = Episcleral venous pressure (8-11
mmHg, exact value calculated based on patient parameters)
Routine tests
At the pre-operative visit when baseline measurements are taken and at each routine
post-operative follow-up visit (1 day, 1 week, 1 month, 3 months, 6 months, and 12 months
after surgery) patients will undergo a clinical ophthalmological examination including the
following tests and examinations:
- Visual acuity measurement (Snellen and ETDRS charts will be used. Best Corrected
Distance Visual Acuity (BCVA) and Non Corrected Distance Visual Acuity (NCVA) will be
measured using ETDRS (early treatment diabetic retinopathy study) charts. Best
Corrected Near Visual Acuity (BCVA) will be measured using a standard near vision
chart).
- Slit lamp examination
- Visual fields
- IOP (intraocular pressure) measurement (Goldmann applanation tonometry will be used to
measure IOP, except when there is irregular corneal astigmatism or other corneal
problems which may preclude accurate reading. The IOP measurement will be done after
application of topical anesthetic (eye drop) with fluorescein)
- Gonioscopy
- Dilated fundoscopy
- Anterior chamber depth and axial length
- Central corneal thickness
- Refraction (routine at baseline only)
Description of the surgical interventions
There are potentially four types of operation that patients may have as part of their
glaucoma care in the department:
- Trans-trabecular meshwork implants (Hydrus implant or iStent implant)
- Ciliary Ablation Treatment (Diode laser or HiFu ultrasound treatment)
- External (sub-conjunctival) Drainage Surgery (Trabeculectomy, Baerveldt implant or
Ahmed Implant)
- Suprachoroidal Shunt Surgery (STARflo)
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02628223 -
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
|
N/A | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 |